AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11591835 — intervention group
Group type: COMPARATOR
Intervention: Placebo in TACS subgroup
Number of subjects: 190
Study 9869786 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% brimonidine tartrate
Number of subjects: 18
Study 9869786 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 18
Study 8087784 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen therapy
Number of subjects: 0
Study 8087784 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 0
Study 8087784 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine therapy
Number of subjects: 0
Study 8087784 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard doses of chemotherapy
Number of subjects: 0
Study 8087784 — intervention group
Group type: EXPERIMENTAL
Intervention: Future clinical trials
Number of subjects: 0
Study 3195529 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics plus 5 mL/kg/d for four days of IgM-enriched immunoglobulin intravenously
Number of subjects: 60
Study 3195529 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics alone
Number of subjects: 60
Study 6897618 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromhexin tablets 8 mg
Number of subjects: 10
Study 6897618 — intervention group
Group type: COMPARATOR
Intervention: Bisolvon tablets 8 mg
Number of subjects: 10
Study 6897618 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromhexin, DAK and Bisolvon
Number of subjects: 10
Study 6897618 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromhexine (overall pharmacokinetics)
Number of subjects: 10
Study 30924785 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring strategy
Number of subjects: 84
Study 29160099 — intervention group
Group type: EXPERIMENTAL
Intervention: rAAV1-CMV-hGAA gene therapy
Number of subjects: 0
Study 26934400 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle ergometer-based exercise program
Number of subjects: 24
Study 26934400 — intervention group
Group type: COMPARATOR
Intervention: Standard physical rehabilitation protocol
Number of subjects: 24
Study 24874911 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized substrate modification (ISM)
Number of subjects: 124
Study 24874911 — intervention group
Group type: COMPARATOR
Intervention: Stepwise ablation (SA)
Number of subjects: 124
Study 23433618 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (postcards with enrollment information)
Number of subjects: 5807
Study 23433618 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (postcards with enrollment and fluoride varnish information)
Number of subjects: 5807
Study 23433618 — intervention group
Group type: COMPARATOR
Intervention: Group 3 (no postcards)
Number of subjects: 5807
Study 20648041 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant sterol margarine
Number of subjects: 53
Study 20648041 — intervention group
Group type: EXPERIMENTAL
Intervention: No-trans-fat margarine
Number of subjects: 53
Study 20648041 — intervention group
Group type: COMPARATOR
Intervention: Butter
Number of subjects: 53
Study 17561982 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT) in Turner syndrome
Number of subjects: 16
Study 17561982 — intervention group
Group type: COMPARATOR
Intervention: Oral contraceptives in controls
Number of subjects: 16
Study 16036040 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibition of the renin‐angiotensin‐aldosterone axis and the sympathetic nervous system
Number of subjects: 0
Study 16036040 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigation of endothelin, matrix metalloproteinases, and cytokines
Number of subjects: 0
Study 12499033 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 microg ethinyl estradiol and 75 microg gestodene (GSD)
Number of subjects: 36
Study 12499033 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 microg ethinyl estradiol and 150 microg desogestrel (DSG)
Number of subjects: 36
Study 9822044 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term treatment protocol (LTP) with PGE1: 2-hour infusions (60 microg PGE1, 5 days each week for 4 weeks), followed by twice a week for 4 weeks, then monitoring for 3 months.
Number of subjects: 109
Study 9822044 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term treatment protocol (STP) with PGE1: 2-hour infusion over 2 days (1st day: morning 20 microg, afternoon 40 microg; 2nd day: morning and afternoon 60 microg), followed by full dosage for subsequent cycles.
Number of subjects: 109
Study 8024636 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (300 mg)
Number of subjects: 12
Study 8024636 — intervention group
Group type: COMPARATOR
Intervention: Famotidine (40 mg)
Number of subjects: 12
Study 2644595 — intervention group
Group type: EXPERIMENTAL
Intervention: Clotrimazole 500 mg vaginal suppositories, administered once weekly for 2 weeks
Number of subjects: 42
Study 2644595 — intervention group
Group type: EXPERIMENTAL
Intervention: Clotrimazole 500 mg vaginal tablets, administered once a month during prophylactic phase
Number of subjects: 42
Study 2644595 — intervention group
Group type: COMPARATOR
Intervention: Placebo, administered once a month during prophylactic phase
Number of subjects: 42
Study 886526 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy with a spread of 60 ± 12 hr
Number of subjects: 121
Study 886526 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy with a spread of 156 ± 12 hr
Number of subjects: 121
Study 30016185 — intervention group
Group type: EXPERIMENTAL
Intervention: LVHL2 (low-velocity, high-load, twice-weekly)
Number of subjects: 54
Study 30016185 — intervention group
Group type: EXPERIMENTAL
Intervention: LVHL1 (low-velocity, high-load, once-weekly)
Number of subjects: 54
Study 30016185 — intervention group
Group type: EXPERIMENTAL
Intervention: HVLL2 (high-velocity, low-load, twice-weekly)
Number of subjects: 54
Study 30016185 — intervention group
Group type: COMPARATOR
Intervention: CON (no-exercise control)
Number of subjects: 54
Study 28151904 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided pulsed radiofrequency (PRF) stimulation on the interfascial area of the TM
Number of subjects: 36
Study 28151904 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound-guided interfascial block (IFB) with 10 mL of 0.6% lidocaine
Number of subjects: 36
Study 25995169 — intervention group
Group type: EXPERIMENTAL
Intervention: Icotinib administered with food
Number of subjects: 22
Study 25995169 — intervention group
Group type: COMPARATOR
Intervention: Icotinib administered without food
Number of subjects: 22
Study 25995169 — intervention group
Group type: EXPERIMENTAL
Intervention: Icotinib pharmacokinetics model
Number of subjects: 22
Study 25995169 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19 genotype influence
Number of subjects: 22
Study 25995169 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and albumin concentration influence
Number of subjects: 22
Study 23956164 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (3 mg/kg/day of elemental iron and multivitamins)
Number of subjects: 209
Study 23956164 — intervention group
Group type: COMPARATOR
Intervention: Multivitamins alone (control group)
Number of subjects: 209
Study 21788264 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft insole with a semi-rigid rearfoot medial wedge
Number of subjects: 24
Study 21788264 — intervention group
Group type: COMPARATOR
Intervention: Soft insole without corrective posting
Number of subjects: 24
Study 19528561 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate (elemental calcium, 1500 mg/d)
Number of subjects: 340
Study 19528561 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 340
Study 17426409 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealant
Number of subjects: 83
Study 17426409 — intervention group
Group type: EXPERIMENTAL
Intervention: CO(2) laser
Number of subjects: 83
Study 17426409 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocoagulation
Number of subjects: 83
Study 15383014 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of elemental iron per day
Number of subjects: 526
Study 15383014 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of elemental iron per day
Number of subjects: 526
Study 15383014 — intervention group
Group type: COMPARATOR
Intervention: 0 mg of elemental iron (placebo)
Number of subjects: 526
Study 11465525 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (1-1.5 mg)
Number of subjects: 31
Study 11465525 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 9682398 — intervention group
Group type: EXPERIMENTAL
Intervention: cell culture-derived vaccine
Number of subjects: 112
Study 9682398 — intervention group
Group type: COMPARATOR
Intervention: egg-derived vaccine
Number of subjects: 112
Study 7801297 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-exposed group (rats)
Number of subjects: 0
Study 7801297 — intervention group
Group type: COMPARATOR
Intervention: Control group (rats)
Number of subjects: 0
Study 3410479 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal (20 g)
Number of subjects: 77
Study 3410479 — intervention group
Group type: COMPARATOR
Intervention: Control (no activated charcoal)
Number of subjects: 77
Study 29742959 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring (TM) programme
Number of subjects: 142
Study 29742959 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 142
Study 28182700 — intervention group
Group type: EXPERIMENTAL
Intervention: Nyaditum resae® (NR)
Number of subjects: 51
Study 28182700 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 25328994 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NACT)
Number of subjects: 33
Study 23642976 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 38
Study 21463471 — intervention group
Group type: EXPERIMENTAL
Intervention: Single flow rate
Number of subjects: 20
Study 21463471 — intervention group
Group type: EXPERIMENTAL
Intervention: Double flow rate
Number of subjects: 20
Study 21463471 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple flow rate
Number of subjects: 20
Study 17916665 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5-10 mg with perindopril 4-8 mg added as needed
Number of subjects: 0
Study 17916665 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 50-100 mg with bendroflumethiazide 1.25-2.5 mg and potassium added as needed
Number of subjects: 0
Study 16433964 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk containing 2.0 g CPP-ACP/l
Number of subjects: 10
Study 16433964 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk containing 5.0 g CPP-ACP/l
Number of subjects: 10
Study 16433964 — intervention group
Group type: COMPARATOR
Intervention: Control milk
Number of subjects: 10
Study 14657887 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut skin prick tests (SPTs) and oral peanut challenges for groups 2 and 4 with positive SPT responses; peanut-specific IgE measurement for groups 2 and 4 with IgE levels < 15 kU/L.
Number of subjects: 7768
Study 10699651 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 49
Study 10699651 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxisylyte
Number of subjects: 49
Study 9099448 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine 30 mg oral dose
Number of subjects: 64
Study 8418692 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical Banded Gastroplasty (VBG)
Number of subjects: 106
Study 8418692 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical Gastric Bypass (GB)
Number of subjects: 106
Study 8418692 — intervention group
Group type: COMPARATOR
Intervention: Isolated Gastric Bypass (IGB)
Number of subjects: 106
Study 3096723 — intervention group
Group type: EXPERIMENTAL
Intervention: Methohexitone 1.5-2 mg kg‐1
Number of subjects: 60
Study 3096723 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2 mg kg‐1
Number of subjects: 60
Study 3096723 — intervention group
Group type: COMPARATOR
Intervention: Alfentanil 7 micrograms kg‐1
Number of subjects: 60
Study 29316946 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined cognitive behavioural group psychotherapy and physiotherapy (9 weekly sessions with a 4-week break between modules)
Number of subjects: 36
Study 29316946 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (Control group)
Number of subjects: 36
Study 26867161 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy (FS) screening
Number of subjects: 3213
Study 26867161 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal immunochemical test (FIT)
Number of subjects: 3213
Study 26867161 — intervention group
Group type: COMPARATOR
Intervention: No screening (control group)
Number of subjects: 3213
Study 26867161 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative screening result
Number of subjects: 3213
Study 26867161 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive screening result
Number of subjects: 3213
Study 25489295 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer coaching intervention
Number of subjects: 540
Study 23265025 — intervention group
Group type: EXPERIMENTAL
Intervention: PBVO2max
Number of subjects: 24
Study 23265025 — intervention group
Group type: COMPARATOR
Intervention: PBPA
Number of subjects: 24
Study 20510642 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention for overweight men
Number of subjects: 0
Study 20510642 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention for overweight women
Number of subjects: 0
Study 18716157 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol (at concentrations detected in plasma after wine intake)
Number of subjects: 20
Study 18716157 — intervention group
Group type: COMPARATOR
Intervention: Control (no resveratrol, just wine intake)
Number of subjects: 20
Study 15882362 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone intervention delivered by a specialist nurse
Number of subjects: 10
Study 15882362 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 10
Study 12666731 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lindane shampoo alone (group 1)
Number of subjects: 7495
Study 12666731 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lindane shampoo and oral trimethoprim/sulfamethoxazole (group 2)
Number of subjects: 7495
Study 10547175 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise program
Number of subjects: 156
Study 10547175 — intervention group
Group type: COMPARATOR
Intervention: Antidepressants (sertraline hydrochloride)
Number of subjects: 156
Study 10547175 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise and medication
Number of subjects: 156
Study 8683243 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifostine (910 mg/m2)
Number of subjects: 242
Study 1805048 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatine (IPM/CS) 1 g twice daily
Number of subjects: 101
Study 1805048 — intervention group
Group type: COMPARATOR
Intervention: Latamoxef (LMOX) 2 g plus Tobramycin (TOB) 90 mg twice daily
Number of subjects: 101
Study 1805048 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatine (IPM/CS)
Number of subjects: 101
Study 1805048 — intervention group
Group type: COMPARATOR
Intervention: Latamoxef (LMOX) plus Tobramycin (TOB)
Number of subjects: 101
Study 6402917 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tegafur (1 gm/m2/days 1‐21)
Number of subjects: 67
Study 6402917 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil (5-Fu, 500 mg/m2/days 1‐4, then 250 mg/m2 on days 6, 8, 10, 12)
Number of subjects: 67
Study 6402917 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients switched to tegafur after failing on 5-Fu
Number of subjects: 67
Study 6402917 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil
Number of subjects: 67
Study 6402917 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tegafur
Number of subjects: 67
Study 31396686 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical assessment including swollen and tender joints count, patient and physician global assessment (PhGA), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP)
Number of subjects: 281
Study 31396686 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound (US) assessment including synovitis or tenosynovitis by grey-scale (GS) and power Doppler (PD) of 42 structures
Number of subjects: 281
Study 31396686 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative scoring method (0/1 based on algorithm)
Number of subjects: 281
Study 31396686 — intervention group
Group type: EXPERIMENTAL
Intervention: UltraSound Activity score (sum of swollen joint count, US qualitative score, and CRP)
Number of subjects: 281
Study 29105958 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol/valsartan SPC (5 mg/80 mg)
Number of subjects: 0
Study 29105958 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol/valsartan SPC (5 mg/160 mg)
Number of subjects: 0
Study 29105958 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol/valsartan SPC (10 mg/160 mg)
Number of subjects: 0
Study 29105958 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol/valsartan SPC (10 mg/320 mg)
Number of subjects: 0
Study 29105958 — intervention group
Group type: COMPARATOR
Intervention: Comparator weighted average (non-β-blocker/renin-angiotensin-aldosterone system inhibitor SPCs)
Number of subjects: 0
Study 27399438 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Disk Replacement (TDR)
Number of subjects: 330
Study 27399438 — intervention group
Group type: COMPARATOR
Intervention: Anterior Cervical Discectomy and Fusion (ACDF)
Number of subjects: 330
Study 25384813 — intervention group
Group type: EXPERIMENTAL
Intervention: BRIGHT screening tool intervention
Number of subjects: 3300
Study 25384813 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 3300
Study 23007716 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-minute slow-stroke back massage (SSBM)
Number of subjects: 40
Study 23007716 — intervention group
Group type: COMPARATOR
Intervention: Usual care control condition
Number of subjects: 40
Study 20829325 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum
Number of subjects: 755
Study 20829325 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling (motivational interviewing)
Number of subjects: 755
Study 20829325 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 755
Study 20829325 — intervention group
Group type: COMPARATOR
Intervention: Counseling (health education)
Number of subjects: 755
Study 17272996 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose interferon-alpha (3 MU three times per week for 12 months)
Number of subjects: 23
Study 17272996 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose interferon-alpha (5 MU three times per week for 6 months)
Number of subjects: 23
Study 17272996 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment (both doses)
Number of subjects: 23
Study 16095546 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-based exercise treatment
Number of subjects: 312
Study 16095546 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 312
Study 12463433 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% glyceryl trinitrate ointment (GTN)
Number of subjects: 70
Study 12463433 — intervention group
Group type: COMPARATOR
Intervention: Lateral internal sphincterotomy
Number of subjects: 70
Study 10513492 — intervention group
Group type: EXPERIMENTAL
Intervention: Training encounter with an arthritis educator along with standard experience in the arthritis clinic (n = 16)
Number of subjects: 27
Study 10513492 — intervention group
Group type: COMPARATOR
Intervention: Standard training in the arthritis clinic only (n = 11)
Number of subjects: 27
Study 10513492 — intervention group
Group type: COMPARATOR
Intervention: Rheumatologists (n = 21) performing a comprehensive musculoskeletal examination
Number of subjects: 27
Study 7677125 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol ester saturated fatty acid palmitic acid (16:0)
Number of subjects: 188
Study 7677125 — intervention group
Group type: EXPERIMENTAL
Intervention: Phospholipid omega‐3 fatty acid docosapentaenoic acid (22:5)
Number of subjects: 188
Study 7677125 — intervention group
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (22:6)
Number of subjects: 188
Study 2188928 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone 12 mg/m2 i.v. every three weeks
Number of subjects: 24
Study 483111 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% mannitol-bisacodyl solution for oral use
Number of subjects: 0
Study 31321771 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pantoprazole 40 mg once daily
Number of subjects: 3291
Study 31321771 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily
Number of subjects: 3291
Study 28624340 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide (20 µg daily)
Number of subjects: 94
Study 28624340 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab (60 mg every 6 months)
Number of subjects: 94
Study 28624340 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Teriparatide and Denosumab
Number of subjects: 94
Study 28624340 — intervention group
Group type: COMPARATOR
Intervention: Denosumab to Teriparatide
Number of subjects: 94
Study 28624340 — intervention group
Group type: COMPARATOR
Intervention: Teriparatide to Denosumab
Number of subjects: 94
Study 28624340 — intervention group
Group type: COMPARATOR
Intervention: Combination to Denosumab
Number of subjects: 94
Study 24620015 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective COX‐2 inhibitors
Number of subjects: 0
Study 24620015 — intervention group
Group type: COMPARATOR
Intervention: Nonselective COX‐2 inhibitors
Number of subjects: 0
Study 23508079 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-TA-assisted PPV without ILM peeling (Group 1)
Number of subjects: 96
Study 23508079 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-TA-assisted PPV with ILM peeling (Group 2)
Number of subjects: 96
Study 23508079 — intervention group
Group type: EXPERIMENTAL
Intervention: TA-assisted PPV without ILM peeling (Group 3)
Number of subjects: 96
Study 23508079 — intervention group
Group type: EXPERIMENTAL
Intervention: TA-assisted PPV with ILM peeling (Group 4)
Number of subjects: 96
Study 21475006 — intervention group
Group type: EXPERIMENTAL
Intervention: StrataGraft skin substitute
Number of subjects: 15